All
Immunotherapy May Move Into Advanced Gynecologic Cancers
July 20th 2017The immunotherapy agent Opdivo (nivolumab) showed clinical acitivty in women who had recurrent/metastatic cervical cancer, and was active to a lesser extent in vaginal and vulvar cancers, according to results from the CheckMate-358 trial.
What’s Next for Drug Price Reforms in Oncology?
July 19th 2017“If you locked everybody in a room for a week, I think we could come up with something that everybody would be comfortable with,” said Blase Polite, M.D., a co-author of the statement, and immediate past chair of ASCO’s government relations committee.
When Is It Time To Find a New Oncologist?
July 18th 2017The doctor-patient relationship is a delicate one. It's one that needs to be comfortable between both parties. When and how do breast cancer patients know when it's time to make a change? This is an important decision that should not be taken lightly.
FDA Approves Nerlynx for HER2-Positive Breast Cancer Treatment
July 18th 2017Nerlynx (neratinib) was granted approval by the Food and Drug Administration (FDA) for the extended adjuvant treatment of patients with early stage, HER2-positive breast cancer who have already received postoperative Herceptin (trastuzumab).